Biotech IPO revival faces competition from cash-rich big pharma buyers

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

This story was reported by Europe News. EUROPES curates Europe's most relevant coverage — read the full report at the original source.